Leave to Appeal in patent dispute over C-RAD’s entitlement to patents granted

The Stockholm Patent and Market court confirmed in its verdict dated July 26, 2019, C‑RAD’s right to the patent application “Ionizing radiation detecting device”. The
opposing party, Beamocular AB, appealed the verdict. Now, the appeal court (Svea Hovrätt- Patent- och marknadsöverdomstolen) has granted leave to appeal.Leave to appeal is granted in the large majority of appeals in patent cases. The decision to leave grant to the appeal does in itself not indicate how the appeal court will rule after having heard the case on the merits.The appeal court will try the case based on the same material as in the district court. C‑RAD’s view is that nothing new has happened, and C-RAD’s assessment of its chances to successfully defend its right to the invention remains unchanged.Background
The background to the dispute relates to a patent entitlement lawsuit that C-RAD filed against Beamocular with the Patent and Market Court in Stockholm on May 22, 2017. C-RAD claims the ownership rights of the invention described in the patent application “Ionizing radiation detecting device” from Beamocular. The ownership in the rights of the patent does not have a significant impact on C‑RADs long-term strategy as the patent is not utilized at the moment.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email tim.turn@c-rad.com
About C-RADC-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.For more information on C-RAD, please visit http://www.c-rad.comAttachmentPR 20191203 Leave to Appeal

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.